250 related articles for article (PubMed ID: 17471006)
21. [Chronic kidney disease-mineral and bone disorder (CKD-MBD)].
Hamada Y; Fukagawa M
Nihon Rinsho; 2006 Sep; 64(9):1703-6. PubMed ID: 16972683
[TBL] [Abstract][Full Text] [Related]
22. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
Kazama JJ
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
[TBL] [Abstract][Full Text] [Related]
23. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
24. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
25. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).
Moe SM; Seifert MF; Chen NX; Sinders RM; Chen X; Duan D; Henley C; Martin D; Gattone VH
Nephrol Dial Transplant; 2009 Aug; 24(8):2371-7. PubMed ID: 19258382
[TBL] [Abstract][Full Text] [Related]
26. Renal Association Clinical Practice Guideline in mineral and bone disorders in CKD.
Steddon S; Sharples E
Nephron Clin Pract; 2011; 118 Suppl 1():c145-52. PubMed ID: 21555893
[No Abstract] [Full Text] [Related]
27. [Mineral and bone disturbances associated with chronic kidney disease].
Suchowierska E; Myśliwiec M
Pol Merkur Lekarski; 2010 Feb; 28(164):138-43. PubMed ID: 20369744
[TBL] [Abstract][Full Text] [Related]
28. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
[TBL] [Abstract][Full Text] [Related]
29. Chronic kidney disease-mineral-bone disorder: a new paradigm.
Moe SM; Drüeke T; Lameire N; Eknoyan G
Adv Chronic Kidney Dis; 2007 Jan; 14(1):3-12. PubMed ID: 17200038
[TBL] [Abstract][Full Text] [Related]
30. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
[TBL] [Abstract][Full Text] [Related]
31. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
[TBL] [Abstract][Full Text] [Related]
32. Secondary hyperparathyroidism: review of the disease and its treatment.
de Francisco AL
Clin Ther; 2004 Dec; 26(12):1976-93. PubMed ID: 15823762
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
34. [Renal osteodystrophy].
Imanishi Y
Clin Calcium; 2007 Oct; 17(10):1521-8. PubMed ID: 17906403
[TBL] [Abstract][Full Text] [Related]
35. [Vitamin D metabolism and chronic kidney disease].
Honda H; Sanada D; Akizawa T
Clin Calcium; 2006 Jul; 16(7):1143-46. PubMed ID: 16816474
[TBL] [Abstract][Full Text] [Related]
36. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
Cozzolino M; Messa P; Brancaccio D; Cannella G; Bolasco P; Di Luca M; Costanzo AM; Paparatti Ud; Festa V; Gualberti G; Mazzaferro S;
Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
[TBL] [Abstract][Full Text] [Related]
37. Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: can we influence patient-level outcomes?
O'Shea S; Johnson DW
Nephrology (Carlton); 2009 Jun; 14(4):416-27. PubMed ID: 19563384
[TBL] [Abstract][Full Text] [Related]
38. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
39. Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach.
Svára F
J Ren Care; 2009 Mar; 35 Suppl 1():3-6. PubMed ID: 19222724
[TBL] [Abstract][Full Text] [Related]
40. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.
Fukagawa M; Komaba H; Onishi Y; Fukuhara S; Akizawa T; Kurokawa K;
Am J Nephrol; 2011; 33(5):427-37. PubMed ID: 21508631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
